LENSAR Inc (LNSR) News

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

44 ALLY® Adaptive Cataract Treatment Systems were placed in 2023, significantly exceeding the target of 30, increasing the ALLY installed base to...

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”) today announced that a majority of the independent members of LENSAR’s board of directors...

Form 8-K - Current report

LENSAR to Report Fourth Quarter and Full Year 2023 Financial Results on Monday, March 4, 2024

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for...

Form 8-K - Current report

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

LENSAR Reports Third Quarter 2023 Results and Provides Business Update

Increased ALLY® Adaptive Cataract Treatment System installed base to 39 systems with a backlog of 8 additional systems for installation as of...